ArticleDiabetologia2012
B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway?
Article in Diabetologia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997.European journal of heart failure · 2018Trial
- Acarbose treatment enhances mid-regional pro-atrial natriuretic peptide concentrations in non-diabetic individuals: further evidence for a common cardiometabolic pathway?Diabetologia · 2012Trial
- LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes.Diabetologia · 2016Article
- Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice.Diabetologia · 2014Article
- A heart-adipose tissue connection in the regulation of energy metabolism.Nature reviews. Endocrinology · 2014Review
- Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice.Endocrinology · 2013Article
- Defending the con side: obesity paradox does not exist.Diabetes care · 2013Article
- Cardiac natriuretic peptides: contributors to cardiac cachexia or possible anti-obesity agents or both?Diabetes · 2012Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There is emerging evidence of cross-talk between the myocardium and systemic metabolic pathways. In particular, there is interest in the potential metabolic effects of A-type and B-type natriuretic peptides (ANP and BNP), produced in the myocardial tissue in response to ventricular stretch and cardiac overload. This commentary provides an overview of the evidence that natriuretic peptides promote lipolysis and enhance adiponectin production. In addition, we review new and existing evidence that BNP may directly improve glucose control, or else lower glucose indirectly via enhanced capillary permeability or greater renal excretion. Further investigation of the links between natriuretic peptide and glycaemia would seem important given the potential to reveal novel mechanisms to treat diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.